- Home
- VINP vs ABVX Comparison
VINP vs ABVX Comparison
Compare VINP & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- ABVX
- Stock Information
- Founded
- VINP 2009
- ABVX 2013
- Country
- VINP Brazil
- ABVX France
- Employees
- VINP N/A
- ABVX N/A
- Industry
- VINP Investment Managers
- ABVX
- Sector
- VINP Finance
- ABVX
- Exchange
- VINP Nasdaq
- ABVX Nasdaq
- Market Cap
- VINP 593.2M
- ABVX 511.3M
- IPO Year
- VINP 2021
- ABVX N/A
- Fundamental
- Price
- VINP $9.57
- ABVX $7.18
- Analyst Decision
- VINP Strong Buy
- ABVX Buy
- Analyst Count
- VINP 2
- ABVX 4
- Target Price
- VINP $13.25
- ABVX $31.50
- AVG Volume (30 Days)
- VINP 49.1K
- ABVX 260.9K
- Earning Date
- VINP 08-06-2025
- ABVX 08-11-2025
- Dividend Yield
- VINP 6.79%
- ABVX N/A
- EPS Growth
- VINP N/A
- ABVX N/A
- EPS
- VINP 0.38
- ABVX N/A
- Revenue
- VINP $126,696,258.00
- ABVX $11,444,012.00
- Revenue This Year
- VINP $70.28
- ABVX $284.20
- Revenue Next Year
- VINP $14.37
- ABVX N/A
- P/E Ratio
- VINP $25.14
- ABVX N/A
- Revenue Growth
- VINP 57.51
- ABVX 128.98
- 52 Week Low
- VINP $8.66
- ABVX $4.77
- 52 Week High
- VINP $11.62
- ABVX $14.16
- Technical
- Relative Strength Index (RSI)
- VINP 47.61
- ABVX 56.72
- Support Level
- VINP $9.41
- ABVX $5.69
- Resistance Level
- VINP $9.70
- ABVX $6.19
- Average True Range (ATR)
- VINP 0.23
- ABVX 0.49
- MACD
- VINP 0.01
- ABVX -0.03
- Stochastic Oscillator
- VINP 43.48
- ABVX 51.66
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.